Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19342 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Zhifa Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Pediatric Hematology-Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major …. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Municipal Administration of Hospitals Incubating Program, Beijing Municipal Health Commission, Capital's Funds for Health Improvement and Research.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Avatrombopag (AVA) is a novel thrombopoietin receptor agonist (TPO‐RA) that has been recently approved as a second‐line therapy for immune thrombocytopenia (ITP) in adults; however, its safety and efficacy data in children are lacking. Here, we demonstrated the efficacy and safety of AVA as second‐line therapy in children with ITP. A multicentre, retrospective, observational study was conducted in children with persistent or chronic ITP who did not respond to or relapsed from previous treatment and were treated with AVA for at least 12 weeks between August 2020 and December 2022. The outcomes were the responses (defined as achieving a platelet count ≥30 × 10 9 /L, twofold increase in platelet count from baseline and absence of bleeding), including rapid response within 4 weeks, sustained response at weeks 12 and 24, bleeding control and adverse events (AEs). Thirty‐four (18 males) patients with a mean age of 6.3 (range: 1.9–15.3) years were enrolled. The median number of previous treatment types was four (range: 1–6), and 41.2% patients switched from other TPO‐RAs. Within 4 weeks, overall response (OR) was achieved in 79.4% patients and complete response (CR, defined as a platelet count ≥100 × 10 9 /L and the absence of bleeding) in 67.7% patients with a median response time of 7 (range: 1–27) days. At 12 weeks, OR was achieved in 88.2%, CR in 76.5% and sustained response in 44% of patients. At 24 weeks, 22/34 (64.7%) patients who achieved a response and were followed up for 24 weeks were evaluated; 12/22 (54.55%) achieved a sustained response. During AVA therapy, median platelet counts increased by week 1 and were maintained throughout the treatment period. The proportion of patients with grade 1–3 bleeding decreased from 52.95% at baseline to 2.94% at 12 weeks, while concomitant ITP medications decreased from 36.47% at baseline to 8.82% at 12 weeks, with only 9 (26.47%) patients receiving rescue therapy 23 times within 12 weeks. There were 61.8% patients with 59 AEs: 29.8% with Common Terminology Criteria for Adverse Events grade 1 and the rest with grade 2. These findings show that AVA could achieve a rapid and sustained response in children with persistent or chronic ITP as a second‐line treatment, with good clinical bleeding control and reduction of concomitant ITP therapy, without significant AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Pediatric Hematology-Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Hemophilia Comprehensive Care Centre, Hematology…
- Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China.
- Department of Hematology, Jiangxi Provincial Children's Hospital, Nanchang, China.
- Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, Beijing, China.
- Hematologic Disease Laboratory, Hematology Centre, Beijing Key Laboratory of Pediatric Hematology-Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Childre…
- Department of Hematology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, China.
ORCID-Profile: Zhifa Wang, Aijun Zhang, Jialu Zhang, Xiaoling Cheng, Runhui Wu
Förderung
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals Incubating Program
- Beijing Municipal Health Commission, Capital's Funds for Health Improvement and Research
Zitieren
APA
Wang, Z., Zhang, A., Xu, Z., Wang, N., Zhang, J., Meng, J., Dong, S., Ma, J., Hu, Y., Ouyang, J., Chen, Z., An, Q., Cheng, X., & Wu, R. (2024). Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. British Journal of Haematology. https://doi.org/10.1111/bjh.19342
Vancouver
Wang Z, Zhang A, Xu Z, Wang N, Zhang J, Meng J, et al. Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. British Journal of Haematology. 2024. doi:10.1111/bjh.19342
BibTeX
@article{Wang2024,
author = {Wang, Zhifa and Zhang, Aijun and Xu, Zhongjin and Wang, Nan and Zhang, Jialu and Meng, Jinxi and Dong, Shuyue and Ma, Jingyao and Hu, Yu and Ouyang, Juntao and Chen, Zhenping and An, Qi and Cheng, Xiaoling and Wu, Runhui},
title = {Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19342}
}
EUVIMED